News
EQS-News: PAION AG issues statement on planned capital measure
EQS-News: PAION AG issues statement on planned capital measure
EQS-Adhoc: PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
EQS-Adhoc: PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
EQS-News: PAION AG announces change in Management Board
EQS-News: PAION AG announces change in Management Board
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company’s Vice Chair of the Board of
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest AG opens 14th plasma collection centre in the Czech Republic
EQS-News: Biotest AG: Biotest AG opens 14th plasma collection centre in the Czech Republic
EQS-News: Biotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic
EQS-News: Biotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic
DGAP-News: Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic
DGAP-News: Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic
DGAP-News: PAION AG reports financial results for the first half-year 2022
DGAP-News: PAION AG reports financial results for the first half-year 2022
DGAP-News: HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
DGAP-News: HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
DGAP-News: Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022
DGAP-News: Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR
DGAP-News: Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR
DGAP-News: Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time
DGAP-News: Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in
DGAP-News: PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
DGAP-News: PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE